Lantern Pharma Inc 2024年度报告

FORM10-K (Mark One)☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year endedDecember 31,2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Common Stock Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of theExchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☒ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control overfinancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect thecorrection of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of theregistrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equitywas last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter:$44,285,965. As of March 17, 2025, the registrant had10,784,725shares of common stock, $0.0001par value per share outstanding. Portions of the registrant’s definitive proxy statement for the registrant’s 2025 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A within 120 daysof the registrant’s year ended December 31, 2024 are incorporated herein by reference into Part III of this Annual Report on Form 10-K. Table of Contents Forward Looking StatementsiiPART I.Item 1.Business1Item 1A.Risk Factors61Item 1B.Unresolved Staff Comments.109Item 1C.Cybersecurity109Item 2.Properties.109Item 3.Legal Proceedings.109Item 4.Mine Safety Disclosures.109PART IIItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.110Item 6.Reserved.111Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations.111Item 7A.Quantitative and Qualitative Disclosures About Market Risk.120Item 8.Financial Statements and Supplementary Data.F-1Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.121Item 9A.Controls and Procedures.121Item 9B.Other Information.122Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.122PART IIIItem 10.Directors, Executive Officers and Corporate Governance.123Item 11.Executive Compensation.123Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.123Item 13.Certain Relationships and Related Transactions, and Director Independence.123Item 14.Principal Accountant Fees and Services.123PART IVItem 15.Exhibit and Financial Statement Schedules.124Item 16.Form 10–K Summary.125i SPECIAL NOTE CONCERNING FORWARD-LOOKING STATEMENTS This Annual Report